Oxford Biomedica PLC

Director's Dealing • Nov 14, 2023

National Storage Mechanism | Additional information

RNS Number : 4264T

Oxford Biomedica PLC

14 November 2023

PDMR Dealings

Oxford, UK - 14 November 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that Dr. Michael Hayden, a Non-Executive Director of the Company has purchased 10,000 ordinary shares of 50p each ("Ordinary Shares") in the Company on 13 November 2023 on the London Stock Exchange at a price of £1.9281. Following this purchase Dr. Michael Hayden holds 26,063 shares representing 0.0269% of the Company.

The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the number of ordinary shares purchased.

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")

a)

Name

Dr. Michael Hayden

2.

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Purchase of shares  

c)

Currency

GBP - British pound

d)

Price(s) and volumes(s)

Price(s)	Volume(s)
£1.9281	10,000

e)

Aggregated information

-Aggregate volume

-Aggregated total

10,000

£19,281.00

f)

Date of the transaction

2023-11-13

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: +44 (0)1865 783 000

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFSVLLLSLIV